Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Codexis Earnings Call: Key Takeaways

Codexis reported strong Q3 2026 revenue growth driven by biocatalysis and significant technical milestones in its Ecosynthesis platform, including 100-gram scale production and improved potency.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthTotal revenue $19.3M vs $8.6M YoY; product sales up 78.5% YTD.
Mgmt ConfidenceHigh confidence in scaling; cited 'fourth consecutive quarterly on-target performance.'
Demand VisibilityTwo new evaluation agreements signed; shifting from technical feasibility to deployment.
Margin TrendsGross margin 74.5% in Q3; full-year 2026 guided to low 70s.
Op. LeverageR&D and SG&A expenses declined YoY despite significant revenue growth.
Vol vs PriceGrowth led by CDX049 enzyme volume and new product approvals.
Segment GrowthBiocatalysis business returning to growth; Ecosynthesis platform gaining innovator traction.
New ClientsSigned feasibility study with siRNA pioneer and evaluation with large biopharma.
Capex & Debt$60M term loan; $42.5M drawn to replace debt; cash runway through 2028.
RegulatorySuccessful FDA interaction regarding Ecosynthesis specifications and comparability arguments.
CommentaryFocusing on disrupting oligonucleotide manufacturing via 70% more capital-efficient enzymatic processes.
New LaunchesEcosynthesis 100-gram scale achieved; plans for 500-gram and kilo-scale readiness.

Growth

Total revenue grew 124% to $19.3M; biocatalysis product sales rose 78.5% year-to-date.

Outlook

Reiterated 2026 revenue guidance of $72M-$76M; targeting 500-gram and kilo-scale production next.

Risks

Management pivoted on specific revenue phasing for new partnerships, citing dynamic funnel timing.

Source

The company's earnings call, NASDAQ: CDXS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Codexis, Inc.: key numbers

Share price
$1.06Close, Nov 16
Market cap
$116M
Shares outstanding
109.6MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Industrial Organic ChemicalsSIC 2860

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Codexis, Inc.

All →
4:24 PM ET 10-Q
Financial Results ▶ Call

Codexis Q3 2026 Results: Net Loss of $8.13M, Loss Narrows

Codexis reported a significant increase in total revenues to $19.26 million for Q3 2026, up from $8.60 million in the prior year, driven primarily by product revenue growth. The company successfully reduced its quarterly net loss to $8.13 million compared to $19.62 million in Q3 2025, while strengthening its cash position through a $24.9 million net equity offering.

Key figure
Net loss $8.13M
4:22 PM ET 8-K
Financial Results

Codexis Financial Results

Codexis reported Q3 2026 revenue of $19.3 million, a significant increase from $8.6 million in the prior year, driven by higher product revenue from new customer launches. The company also highlighted a new $60 million term loan facility with Trinity Capital and the successful scale-up of its ECO Synthesis Manufacturing Platform to 100-gram scale.

Term
Q3 2026

“I am pleased with our outstanding progress in 2026, through both innovation and technical achievements, that has garnered attention from leading innovators in the siRNA field.”

Alison Moore, PhD, President and Chief Executive Officer

“We have made significant progress in industrializing our technology while simultaneously increasing our revenue base, managing expenses, and improving the financial stability of our company.”

Alison Moore, PhD, President and Chief Executive Officer
7:33 AM ET 8-K
Loan & Debt

Codexis $60M Debt Financing with Trinity Capital Inc.

Codexis entered into a $60 million Loan and Security Agreement with Trinity Capital, consisting of a $42.5 million initial tranche and $17.5 million in subsequent tranches. The debt is secured by substantially all company assets and carries a variable interest rate with an interest-only period extending up to November 2030. The facility provides capital to support operations while maintaining a financial covenant tied to the company's market capitalization.

Value
$60M
Counterparty
Trinity Capital Inc.
Term
5 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.